Bendamustine hydrochloride

SKU: orb1310942

Description

Bendamustine hydrochloride

Research Area

Cell Biology, Molecular Biology

Key Properties

• CAS Number: 3543-75-7
• MW: 394.72
• Purity: 98.03%
• Formula: C₁₆H₂₁Cl₂N₃O₂·HCl
• SMILES: Cl.Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl
• Target: DNA/RNA Synthesis,DNA Alkylator/Crosslinker,Apoptosis
• Solubility: Ethanol:14 mg/mL (35.47 mM);H2O:2 mg/mL (5.07 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (5.07 mM);DMSO:60 mg/mL (152.01 mM)

Bioactivity

• Target IC50:
  DNA damage 50 μM
• In Vivo:
  Bendamustine causes more extensive and effective DNA Single- and double-st and breaks than cyclophosphamide, Cisplatinum, or carmustine.Bendamustine inhibits mitotic assays and causes mitotic mega-mutations.Bendamustine regulates genes involved in apoptosis, DNA repair, and mitotic assays. Bendamustine had a very low teratogenic effect compared to an equimolar dose of Lomustine.26% of Bendamustine-treated MCF-7/ADR cells showed micronucleation compared to 6% of DMSO-treated cells. Bendamustine alone at concentration ranging from 1 μg mL to 50 μg mL showed dose- and time-dependent effects with toxicity ranging from 30.4% to 94.8% observed after 48 hours the LD50 of untreated and pretreated CLL cells was 7.3 or 4.4 μg/ml, respectively Bendamustine treatment of SU-DHL-9 cells resulted in a 60% to 80% down-regulation o the mRNA expression of All three of these genes (polo-like kinase 1, Aurora kinase A, and cyclin B1). Bendamustine acts on non-Hodgkin's lymphocytes and uniquely regulates DNA repair pathways compared to Other alkylating agents. Myeloid and breast cancer cells are resistant to Bendamustine, but HL-60 cells are moderately sensitive to Bendamustine.
• In Vitro:
  Bendamustine causes more extensive and effective DNA Single- and double-st and breaks than cyclophosphamide, Cisplatinum, or carmustine.Bendamustine inhibits mitotic assays and causes mitotic mega-mutations.Bendamustine regulates genes involved in apoptosis, DNA repair, and mitotic assays. Bendamustine had a very low teratogenic effect compared to an equimolar dose of Lomustine.26% of Bendamustine-treated MCF-7/ADR cells showed micronucleation compared to 6% of DMSO-treated cells. Bendamustine alone at concentration ranging from 1 μg mL to 50 μg mL showed dose- and time-dependent effects with toxicity ranging from 30.4% to 94.8% observed after 48 hours the LD50 of untreated and pretreated CLL cells was 7.3 or 4.4 μg/ml, respectively Bendamustine treatment of SU-DHL-9 cells resulted in a 60% to 80% down-regulation o the mRNA expression of All three of these genes (polo-like kinase 1, Aurora kinase A, and cyclin B1). Bendamustine acts on non-Hodgkin's lymphocytes and uniquely regulates DNA repair pathways compared to Other alkylating agents. Myeloid and breast cancer cells are resistant to Bendamustine, but HL-60 cells are moderately sensitive to Bendamustine.
• Cell Research:
  SU-DHL-1 and SU-DHL-9 cells are preincubated for 30 minutes with either 6 mM methoxyamine or 50 μM O6-benzylguanine, inhibitors of Ape-1 base excision repair enzyme, or alkylguanyl transferase enzyme, respectively the cells are then exposed to various concentration of Bendamustine for 72 hours. Cytotoxicity is evaluated b the MTT viability assay and an IC50 is determined a the drug concentration that inhibited by 50 the viability value o the untreated control. Analyses are done.(Only for Reference)

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Disclaimer: For research use only

Alternative Names

Bendamustine, Bendamustine HCl, DNAAlkylator, DNA synthesis, DNA Synthesis, DNA Alkylator/Crosslinker, DNA Alkylator, DNASynthesis, Crosslinker, Apoptosis, antimetabolite, SDX 105, SDX105, SDX-105, SDX-105 (Cytostasane) HCl, EP 3101, EP3101, RNA Synthesis, RNASynthesis

Compound Identifiers

PubChem CID

77082